SCHEMBL2817036

SCHEMBL2817036

CS(=O)(=O)Oc1nc(C2CC2)cc(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)c1C#N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.46
FLT3 P36888 4/20 0.46
NTRK1 P04629 3/20 0.46
KIT P10721 3/20 0.46
JAK2 O60674 2/20 0.46
CSF1R P07333 2/20 0.46
FLT1 P17948 2/20 0.46
FLT4 P35916 2/20 0.46
NTRK2 Q16620 2/20 0.46
AURKB Q96GD4 2/20 0.46
CHEK1 O14757 1/20 0.46
IKBKB O14920 1/20 0.46
RPS6KA5 O75582 1/20 0.46
PRKD3 O94806 1/20 0.46
RPS6KB1 P23443 1/20 0.46
CDK2 P24941 1/20 0.46
MARK3 P27448 1/20 0.46
EPHA2 P29317 1/20 0.46
AXL P30530 1/20 0.46
MAPKAPK2 P49137 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2820485 0.97 KCNJ6 (0.46) KDRFLT3NTRK1KITJAK2
SCHEMBL2819466 0.96 KDR (0.44) KDRFLT3NTRK1KITJAK2
SCHEMBL4421882 0.92 DGAT1 (0.45) KDRFLT3NTRK1KITJAK2
SCHEMBL4428021 0.89 DGAT1 (0.47) KDRFLT3NTRK1KITJAK2
SCHEMBL4426084 0.88 KCNJ6 (0.45) KDRFLT3NTRK1KITJAK2
SCHEMBL2817273 0.88 KDR (0.43) KDRFLT3NTRK1KITJAK2
SCHEMBL2819256 0.84 GAA (0.51) KDRGAAMEN1MAPTHTT
SCHEMBL2816876 0.83 IDH2 (0.49) KDRFLT3NTRK1KITJAK2
SCHEMBL4431922 0.81 MEN1 (0.43) KDRFLT3NTRK1KITJAK2
SCHEMBL2816155 0.80 KDR (0.53) KDRFLT3NTRK1KITJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7846928-B2 Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-12-07 US disclosed
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058326-A1 SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, FLT1 KDR 1/4885FLT3 39/4885NTRK1 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.